Should you buy this medium-sized pharmaceutical stock after 10% of the accident?
Blue Jet Healthcare Stock Price Target: Medium-sized pharmaceutical company stock – Blue Jet Healthcare – 10% stock Tuesday (July 22). Despite this fall, Macquarie analysts’ stock is a global broker, and this collapse is expected to have 10% room for upside.
The broker’s analysts rated pharmaceutical stocks as “outperforming the market” with a target of Rs 1,000, indicating a 10.35% increase. The broker noted that quarterly earnings (Q1FY26) were subject to one-time inventory charges and adjusted EBITDA and adjusted PAT based on our estimates.
According to the brokerage firm, management pointed out plans to release several products in the comparative media department.
Tuesday’s crash
Blue Jet Healthcare (July 22) fell 10%, with a daily low of Rs 90.6.6.15 in NSE. The stock’s movement comes after announcing its first-quarter earnings.
Blue Jet Healthcare Q1FY26 Results
The company reported its net profit fell 17% to Rs 9.1 billion, compared with Rs 1.1 billion in the fourth millennium.
In the quarter, Blue Jet Healthcare reported revenue of Rs 35.4 crore, up 4.4 per cent, more than double the Rs 16.2 crore recorded in the same period last year.
The company’s EBITDA fell by 13.1% to a quarter of Rs 12.1 crore. However, this has increased by nearly three times year-on-year.
Compared with the same period last year, EBITDA margin signed more than 700 basis points from the March quarter, but showed improvement.
(Disclaimer: The views/advices/advices expressed here in this article are only by investment experts. Zee Business recommends that its readers consult their investment advisors before making any financial decisions.)
